{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:37:08Z","timestamp":1773290228101,"version":"3.50.1"},"reference-count":16,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2003,8,29]],"date-time":"2003-08-29T00:00:00Z","timestamp":1062115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2003,11,20]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>CMM is the most serious cutaneous malignancy and is increasing in frequency among most Caucasian populations, where the most important risk factor is exposure to UV light. Relatively little is known of the genetic factors that mediate susceptibility to and prognosis in sporadic CMM, although a number of genes have been implicated. A striking association between <jats:italic>EGF<\/jats:italic> polymorphism and Breslow thickness of invasive CMM has been reported. We have sought confirmation of this finding in an independent study of 159 patients and 310 controls using TaqMan fluorescence\u2010based genotyping for <jats:italic>EGF<\/jats:italic> +61. In our study group, there were no significant differences in <jats:italic>EGF<\/jats:italic> genotype frequencies between patients and controls nor was <jats:italic>EGF<\/jats:italic> genotype associated with tumour growth phase, stage or mitotic count. However, correlation between <jats:italic>EGF<\/jats:italic> genotype and Breslow thickness showed a modestly significant increase in frequency of the <jats:italic>EGF<\/jats:italic> (G\/G) genotype among tumours &gt;3.5 mm thick (30.0% <jats:italic>vs.<\/jats:italic> 9.8%, <jats:italic>p<\/jats:italic> = 0.03). In summary, in our group, the <jats:italic>EGF<\/jats:italic> +61 polymorphism was not a risk factor for CMM susceptibility, but this polymorphism may play a role in disease progression. \u00a9 2003 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ijc.11448","type":"journal-article","created":{"date-parts":[[2003,9,26]],"date-time":"2003-09-26T09:39:41Z","timestamp":1064569181000},"page":"673-675","source":"Crossref","is-referenced-by-count":49,"title":["<i>EGF<\/i> +61 gene polymorphism and susceptibility to and prognostic markers in cutaneous malignant melanoma"],"prefix":"10.1002","volume":"107","author":[{"given":"Sarah L.","family":"McCarron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian C.","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey M.","family":"Theaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Martin","family":"Howell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,9,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018432632528"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/5.10.1663"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0022-202x.2001.01421.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0215(20011120)95:6<388::AID-IJC1069>3.0.CO;2-6"},{"key":"e_1_2_6_6_2","first-page":"5612","article-title":"A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer","volume":"60","author":"Winsey SL","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1995.332"},{"key":"e_1_2_6_8_2","first-page":"498","article-title":"Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma","volume":"6","author":"Hutchinson PE","year":"2000","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199906000-00001"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910590413"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.1998.tb03025.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gene.6363726"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gene.6363851"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07600-6"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/16.3.1215"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)91539-K"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011043412634"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.11448","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.11448","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T22:23:43Z","timestamp":1697235823000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.11448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,9,24]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,11,20]]}},"alternative-id":["10.1002\/ijc.11448"],"URL":"https:\/\/doi.org\/10.1002\/ijc.11448","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,9,24]]}}}